Successful companies don't stand still. They're always evolving. Today, I'm looking at the changes taking place at FTSE 100 pharmaceuticals giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) - and what they mean for investors.
US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) have both had very different fortunes since the beginning of the year. On one hand, AstraZeneca's shares have surged higher around 15%, beating the FTSE 100 approximately 14%.
In this video series, Mark Rogers asks why particular shares have made headlines in recent days. Under his and Chris Nials' scrutiny this time round are GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Berkshire Hathaway (NYSE: BRK-B.US).
Although the pharmaceutical sector has been hammered by the effect of patent expirations in recent times, GlaxoSmithKline's pre-emptive decision to invest heavily in R&D is clearly paying off handsomely. The firm's 2013 results released last week ...